BioCryst awarded up to $69M HHS contract for RAPIVAB supply to Strategic National Stockpile

BIOCRYST PHARMACEUTICALS INC

Contract covers up to 95,625 doses of RAPIVAB over five years for influenza treatment.
First ordering period executed at $13.9M for 19,125 doses to be supplied by Sept 2025.
Awarded by HHS ASPR; four optional 12-month ordering periods remain.
Prior CDC contract of $34.7M for up to 50,000 doses concluded in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.